Total Reports
34
Below-median volume
Breed profile · FDA CVM July 2026 extract
Adverse-event filings for Coonhound - Redtick (Dog) in the FDA Center for Veterinary Medicine openFDA extract. Browse dog breeds, reactions, and outcomes below.
By recorded gender -- every report on file for Coonhound - Redtick, no filtering.
Data updated September 2026
The verdict
According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Coonhound - Redtick ranks #308 of 510 by total reports (34). Death-coded-share rank requires at least 50 reports. National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).
Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.
Release-over-release change
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Coonhound - Redtick has 34 reports now versus 33 in that prior snapshot: 1 more (3.0%).
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Coonhound - Redtick changesTotal Reports
34
Below-median volume
Deaths Reported
1
of 34 reports
Death-coded share of reports
2.9%
2.9% death-coded
Avg Age at Report
5.2 yr
29.6 kg avg weight
2.9% of 34 coonhound - redtick reports involved a death outcome.
Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
| Year | Reports | Trend |
|---|---|---|
| 2012 | 1 | |
| 2013 | 1 | |
| 2014 | 1 | |
| 2015 | 2 | |
| 2017 | 3 | |
| 2018 | 1 | |
| 2019 | 4 | |
| 2020 | 1 | |
| 2021 | 2 | |
| 2022 | 3 | |
| 2023 | 6 | |
| 2024 | 6 | |
| 2025 | 2 | |
| 2026 | 1 | |
Signature read: Coonhound - Redtick's 2.9% death-coded share is in the lower third of the ≥50-report cohort (median 4.8%). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Coonhound - Redtick sits at #309 of 510 by report volume among all breeds and #208 of 298 among dog breeds, with 34 reports and 1 (2.9%) death-coded. Mean age at report: 5.2 years, average weight 29.6 kg (65.3 lbs).
Top reported signs: Lack of efficacy (endoparasite) - heartworm (6), Lethargy (see also Central nervous system depression in 'Neurological') (4), Vomiting (3). Most-referenced drug: Moxidectin (5 reports), followed by Ivermectin + Pyrantel As Pamoate Salt (4) and Afoxolaner (4).
Outcome coding on 34 status-recorded reports is dominated by Ongoing (41.2%). Annual submissions ranged 1-2,026 across 14 years on file.
Showing 6 of 297 dog breeds in our dataset, ranked by closest report volume.
Two openFDA-derived peer sets for Coonhound - Redtick, both outside the Dog family so the neighborhoods are not species containment (the similar-volume list above stays within species).
Nearest other-species breeds by reported average weight (29.6 kg here).
What to do with this dog
A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.
Compare a breed's report volume against how common the breed is before drawing conclusions. See our methodology for how the death-coded share and rankings are computed, or read breed-specific reporting patterns and FDA CVM reporting.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →